当代心力衰竭临床试验中老年患者、女性及少数族裔入组情况:系统综述
IMPORTANCE: Despite the importance of age, sex, and race/ethnicity representativeness in clinical trials, limited data exist regarding the enrollment trends of these groups in contemporary heart failure (HF) trials.…
要点
- 心衰试验中老年患者和女性代表性持续不足,与流行病学数据存在差距。
- 仅55%的试验报告种族/族裔分布,非白种患者入组比例随时间显著增加。
- HFpEF试验入组患者年龄更大、女性比例更高,但各项试验中女性和老年患者比例仍低于流行病学数据。
核心结论
- 当代心衰临床试验中老年患者和女性持续被低估。
- 种族/族裔数据仅在不到一半的试验中报告,但报告时显示非白种患者入组随时间增加。
研究设计与样本
- 将试验结果与按住院状态和射血分数索引的大型流行病学研究进行比较。
主要发现
- 试验中位入组人数994例(IQR 543-1899),来自中位82个研究站点(IQR 28-171)。
- 94项试验(80%)仅入组射血分数降低的心衰(HFrEF)患者。
关键数值与推荐
- 美国流行病学研究中HFrEF平均年龄69岁,HFpEF和AHF均为73岁。
- 流行病学研究中HFpEF、HFrEF和AHF试验的女性加权比例分别为62%、29%和50%。
临床怎么用
- 心内科医生在解读心衰临床试验结果时,需注意老年患者和女性代表性不足可能限制结果外推。
- 关注种族/族裔数据的报告情况,以评估试验人群的多样性。
局限性
- 仅55%的试验报告了种族/族裔分布,可能导致该方面数据不完整。
- 试验结果与流行病学研究的比较可能受研究设计和人群差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite the importance of age, sex, and race/ethnicity representativeness in clinical trials, limited data exist regarding the enrollment trends of these groups in contemporary heart failure (HF) trials. OBJECTIVE: To characterize the representation of older patients, women, and racial and ethnic minorities in HF trials. EVIDENCE REVIEW: We performed a systematic search of HF trials enrolling more than 400 participants published between January 2001 and December 2016 using PubMed/Medline and ClinicalTrials.gov. A total of 118 trials enrolling a cumulative 215 508 patients were included. Trial findings were compared with large epidemiologic studies indexed to hospitalization status and ejection fraction. FINDINGS: Median number of participants per trial was 994 (interquartile range [IQR], 543-1899), enrolled from a median of 82 (IQR, 28-171) study sites. Overall, 94 trials (80%) enrolled patients with HF with reduced ejection fraction (HFrEF) exclusively. Mean (SD) age of trial participants was 65 (11) years (from 64 years in 2001 to 2004 to 65 years in 2013 to 2016), and 58 873 of 215 508 were women (27%; from 26% in 2001 to 2004 to 29% in 2013 to 2016); no significant temporal trends were observed (P ≥ .60 for both). Chronic HF with preserved ejection fraction (HFpEF) trials enrolled older participants (mean [SD] age, 71 [7] years compared with 65 [11] years for HFrEF and 66 [12] years for acute HF [AHF] trials; P = .01). Corresponding mean ages in US epidemiologic studies were 69 years for HFrEF and 73 years for both patients with HFpEF and patients with AHF. The HFpEF trials had a higher proportion of women (n = 4940 of 8845 [56%]) compared with HFrEF (n = 34 397 of 143 538 [24%]) or AHF (n = 11 013 of 34 633 [32%]) (P < .001). Corresponding weighted proportions of women in HFpEF, HFrEF, and AHF trials in epidemiologic studies were 62%, 29%, and 50%, respectively. Distribution of racial/ethnic groups was reported in 55% (47%) of the trials; 22% of the participants were not white (n = 27 463 of 124 980), with significant increase over time from 13% in 2001 to 2004 (n = 5606 of 44 616) to 30% in 2013 to 2016 (8421 of 28 073) (P = .01). CONCLUSIONS AND RELEVANCE: In contemporary HF trials, older patients and women are consistently underrepresented. Race/ethnicity data are reported in less than half of trials; when reported, such data show that enrollment of nonwhite patients increased over time.
引用
- Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018. PMID: 30140928. doi:10.1001/jamacardio.2018.2559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。